TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Quantum Biopharma ( (TSE:QNTM) ) is now available.
On December 1, 2025, Quantum BioPharma announced the airing of the final segment of a three-part investigative series by CTV News’ W5, highlighting the company’s USD $700 million lawsuit against CIBC and RBC for alleged stock market manipulation. The series sheds light on ‘stock spoofing’, a tactic illegal in Canada and the U.S., which Quantum claims has impacted its operations. The company is committed to protecting its shareholders and advancing its research, particularly in multiple sclerosis, while encouraging others to stand against market manipulation.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company is advancing its lead compound, Lucid-MS, aimed at treating multiple sclerosis by preventing and reversing myelin degradation. Quantum BioPharma also retains a stake in Unbuzzd Wellness Inc., which markets an OTC product for alcohol misuse, and maintains strategic investments through its subsidiary, FSD Strategic Investments Inc.
YTD Price Performance: 140.17%
Average Trading Volume: 4,576
Technical Sentiment Signal: Sell
Current Market Cap: C$53.63M
See more data about QNTM stock on TipRanks’ Stock Analysis page.